Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA nano-teams with academia

This article was originally published in The Tan Sheet

Executive Summary

FDA collaborates with the Alliance for NanoHealth to hasten development of novel medical products using nanotechnology. The FDA/ANH Nanotechnology Initiative aims to expand understanding of how nanoparticles affect biologic systems and develop processes to potentially mitigate nano-related risks, all of which will be placed in the public domain. FDA March 10 said the collaboration is part of its Critical Path initiative for biomarker validation, better clinical trial design and new manufacturing methods (1"The Tan Sheet" Oct. 3, 2005, p. 7)

You may also be interested in...



Von Eschenbach Likely To Put FDA Critical Path Initiative Back On Track

The appointment of National Cancer Institute Director Andrew von Eschenbach to FDA acting commissioner is likely to revitalize the agency's stalled Critical Path initiative

EU Regulatory Round-Up, February 2020: Brexit And Swixit Threaten Huge Disruption Amidst MDR Uncertainty

Complying with the EU’s new Medical Device Regulation would be hard enough. But more layers of uncertainty – especially Brexit and Swixit ̶ mean European medtech is navigating very turbulent waters right now.

Emerging Markets Help Fresenius Kabi Offset US Pressures

Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.

Topics

UsernamePublicRestriction

Register

PS102701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel